Biogen Announces Positive Phase II Results for Alzheimer’s Treatment

Posted by ISPE Boston
On July 19, 2018

Biogen and its partner Eisai have announced positive topline results from the Phase II study with anti-amyloid beta protofibril antibody BAN2401 in 856 patients with early Alzheimer’s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer’s Disease Composite Score or ADCOMS, a measure of […]

Pfizer to Organize into Three Businesses

Posted by ISPE Boston
On July 19, 2018

Pfizer has announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These changes will be […]

Visterra to be Acquired by Otsuka Pharmaceutical for $430M

Posted by ISPE Boston
On July 19, 2018

Otsuka Pharmaceutical, headquartered in Tokyo, and Waltham-based Visterra have announced that Otsuka will acquire Visterra for approximately $430M in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction which is expected to close in the third quarter of 2018. Visterra’s Hierotope platform, comprised of novel computational and experimental technologies, enables […]

Rubius Therapeutics Selects Rhode Island for Manufacturing Facility

Posted by ISPE Boston
On July 5, 2018

Rhode Island Governor Gina Raimondo has announced that biotech company Rubius Therapeutics is planning to establish a manufacturing facility in Rhode Island that will create 160 high-skilled jobs in manufacturing, biotech operations and other support functions. Rubius intends to invest up to $155 million over a more than five-year period to renovate a 135,000-square-foot manufacturing […]

Local Biotechs Akebia and Keryx to Merge

Posted by ISPE Boston
On July 5, 2018

Akebia Therapeutics and Keryx Biopharmaceuticals (based in Cambridge and Boston, respectively) have announced a definitive merger agreement under which the companies will combine in an all-stock merger. The transaction will create a fully integrated biopharmaceutical company called Akebia Therapeutics focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 […]

Broad and Bayer Expand Partnership, Launch New Research Effort

Posted by ISPE Boston
On July 5, 2018

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure. According to the American Heart Association, more than 900,000 people are diagnosed with heart failure every year in the United States. The condition, […]

Kaleido Biosciences Raises $101 Million to Develop Microbiome Therapies

Posted by ISPE Boston
On June 28, 2018

Bedford-based Kaleido Biosciences, a clinical-stage healthcare company developing novel chemistries to drive functions of the microbiome organ, has raised $101 million in an oversubscribed Series C financing. Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform. “We […]

Chapter Leaders Attend Life Sciences Bill Signing

Posted by Brian Hagopian
On June 21, 2018

On Friday, June 15, Governor Charlie Baker Signed Bill H 4501 providing up to $623 million dollars to support Massachusetts’ life sciences ecosystem over the next five years – and the Boston Area Chapter was thrilled to be invited to attend. By approving the bill, the Commonwealth stepped up big time and showed its continued […]

WuXi Biologics Chooses Worcester for First U.S. Manufacturing Facility

Posted by ISPE Boston
On June 21, 2018

WuXi Biologics of Shanghai has announced that it plans to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester. The Worcester facility will be WuXi Biologics’ first overseas site in the U.S. WuXi Biologics is a leading global platform company providing end-to-end solutions for […]

Sage Announces Results of FDA Breakthrough Therapy Meeting

Posted by ISPE Boston
On June 21, 2018

Sage Therapeutics has announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the FDA. This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). “Sage is excited to receive feedback from the […]

Page 1 of 1012 3 ›»